clinical trial · NCT04030026
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
Idiopathic Pulmonary FibrosisNAL ERPlacebo
brief summary
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared to placebo tablets.
started
Oct 29, 2019
primary completion
May 27, 2022
completion
May 27, 2022
last updated
May 29, 2025
official title
A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol